Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus polymeric nanoparticle - Samyang

Next Previous
Drug Profile

Sirolimus polymeric nanoparticle - Samyang

Alternative Names: PNP-sirolimus; Sirolimus PNP

Latest Information Update: 21 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 21 Mar 2023 Discontinued - Preclinical for Cancer in South Korea (IV)
  • 17 Jan 2019 Sirolimus polymeric nanoparticle is still in preclinical trials for Cancer in South Korea (Samyang Biopharmaceuticals pipeline, January 2019)
  • 01 Aug 2012 Nanopolymer sirolimus is available for licensing worldwide as of 01 Aug 2012. http://www.samyangbiopharm.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top